Argireline: the basics
What is it?
A lab-made chain of six amino acids designed to copy a small part of SNAP-25, a protein nerves use to tell muscles to tighten. It is used in skin creams.
Research paper 1 ↗Research paper 2 ↗Research paper 3 ↗Research paper 4 ↗What do people claim it helps with?
Called a 'Botox-like' or 'Botox in a jar' ingredient that softens frown lines and crow's feet. That comparison is marketing, not an established medical effect.
What has research actually shown?
In lab tests it partly blocked the machinery nerves use to send signals. Small skin-cream trials report modest wrinkle improvements, and an NIH eyelid-spasm pilot did not show a clear benefit.
Research paper 1 ↗Research paper 2 ↗Research paper 3 ↗Research paper 4 ↗Has this been demonstrated in people?
Laboratory experiments plus a handful of small human skin-cream studies lasting a few weeks. Large, independent, long-term trials are missing.
Research paper 1 ↗Research paper 2 ↗Research paper 3 ↗Research paper 4 ↗What side effects, risks and unknowns should I understand?
Creams are generally reported as well tolerated. Injecting it is not an approved use; one case report describes a serious skin infection after facial injections.
Research paper 1 ↗Research paper 2 ↗Is it an approved medicine?
No FDA-approved medicine contains this peptide. It is a cosmetic ingredient, and FDA does not pre-approve cosmetic ingredients.
FDA safety information 1 ↗FDA safety information 2 ↗Approval here means U.S. FDA approval and applies to a particular product, formulation and use. This is a starting overview, not a complete side-effect list. Sources checked 10 October 2026; independent scientific review pending.
How is it used or studied?
Used in topical creams and serums. Lab tests show very little gets past the outer skin layer, which limits what a cream can do.
Different routes and formulations can have different effects. A study of one product does not validate every product with the same peptide name.
A common misunderstanding
Acetyl hexapeptide-3 and acetyl hexapeptide-8 are two names for the same ingredient. SNAP-8 is a related but different, longer peptide.
What should I ask a clinician?
- What diagnosis or goal are we trying to address, and what established options are available?
- Was the expected benefit shown in people like me, using this exact product?
- How could my medicines, health conditions or pregnancy plans affect the risks?
- What monitoring is needed, and what would tell us the treatment is helping or should be stopped?
What do the research words mean?
- Peptide
- A short chain of amino acids, the building blocks of proteins.
- Preclinical
- Research in cells, tissues or animals before dependable treatment evidence in people.
- Controlled trial
- A study comparing a treatment with another treatment or a placebo to help separate its effects from other explanations.
- Biomarker
- A measurement, such as a hormone level. A change does not necessarily mean someone feels better or lives longer.
Argireline Evidence & Clinical Profile
Human Study Limits
Argireline has been investigated in clinical contexts. Patient outcomes must be evaluated against study size, design, and control cohorts.
Laboratory & In Vivo Assays
Cellular and animal disease models examine receptor binding affinities and signaling cascades, which require human confirmation.
What is Argireline?
Acetyl Hexapeptide-3 (Acetyl Hexapeptide-8) is Argireline is a six-amino-acid peptide designed to mimic part of SNAP-25, a protein nerve endings use to release signals to muscles. It is sold as a cosmetic ingredient, not a medicine. Small trials report modest wrinkle improvements, but laboratory work shows very little of it gets past the skin surface. Aliases include: Acetyl Hexapeptide-3, Acetyl Hexapeptide-8, Acetyl Hexapeptide-8 Amide, Ac-EEMQRR-NH2, AH-8.
- Sequence (one-letter)
- Ac-EEMQRR-NH2
- Molecular formula
- N/A
- Molecular weight
- N/A
- CAS Number
- 616204-22-9
- UNII Code
- L4EL31FWIL
- PubChem CID
- 71587772
Molecular formula and weight are not shown because the PubChem record’s computed formula does not match the stated sequence; FDA GSRS gives none.
Identifiers checked against PubChem and FDA's Global Substance Registration System on 13 October 2026. FDA substance record ↗ · PubChem record ↗ See all names and codes in the peptide name index.
Clinical Trials & Human Cohorts
Human research can examine tolerability, symptoms or patient outcomes. The design and comparator determine what each result can establish.
The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study [2]
What was reported
Investigators rated about half of the argireline group as improved versus none on placebo; skin-replica roughness measures decreased with argireline.
What limits the conclusion
Short, single-center, unequal groups; blinding details limited in the abstract. The same group published overlapping reports of this work.
Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy [3]
What was reported
No significant adverse events. Only a non-significant trend toward a longer period of symptom control after each toxin injection.
What limits the conclusion
Pilot size; primary outcome was not statistically significant. Two co-authors were from a peptide manufacturer. A follow-up NIH trial was terminated with 8 participants.
Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet [4]
What was reported
Some participants improved, but the acetyl hexapeptide-3 cream appeared less effective than the palmitoyl pentapeptide-4 cream.
What limits the conclusion
Very small groups; described by the authors as an initial study.
How the compound may work
Mechanisms describe how Argireline may affect biological processes. Laboratory findings and patient outcomes answer different questions.
SNARE-complex interference
Argireline came from a design programme seeking a non-toxic mimic of botulinum toxin's effect. In laboratory tests it interfered with formation of the SNARE complex that nerve endings need to release signals, with far lower efficacy than botulinum toxin. [1]
Limited skin penetration
Most of the peptide applied in a cosmetic emulsion washed off. What penetrated stayed mainly in the outer stratum corneum; none was detected in the dermis. This makes a muscle-level effect from creams uncertain. [5]
Areas Being Studied
These research topics reflect active areas of scientific exploration, distinct from unverified commercial marketing claims.
Expression wrinkles
A 2025 review describes possible reductions in wrinkle depth but stresses low skin penetration and uncertainty about whether the peptide reaches nerve-muscle junctions. [7]
Blepharospasm add-on
Tested as a cream alongside botulinum toxin; results were not significant and a second trial stopped early. [3]
Injection misuse
A woman developed a Mycobacterium abscessus skin infection after argireline was injected into her face. It is not an approved injectable product. [8]
Compare the study designs.
| Study | Design / sample | Outcome type | Key limitation |
|---|---|---|---|
| Periorbital wrinkles, China · 2013 [2] | Randomized placebo-controlled topical study (3:1 allocation), 4 weeks n = 60 |
Clinical endpoint evaluation | Short, single-center, unequal groups; blinding details limited in the abstract. The same group published overlapping reports of this work. |
| Blepharospasm pilot (NIH) · 2013 [3] | Double-blind, placebo-controlled randomized pilot alongside routine botulinum toxin injections n = 24 |
Clinical endpoint evaluation | Pilot size; primary outcome was not statistically significant. Two co-authors were from a peptide manufacturer. A follow-up NIH trial was terminated with 8 participants. |
| Crow's feet pilot · 2023 [4] | 8-week double-blind randomized three-arm trial n = 21 |
Clinical endpoint evaluation | Very small groups; described by the authors as an initial study. |
Regulatory Status & Clinical Safety
Regulatory Classification
United States, checked 11 October 2026: acetyl hexapeptide-8 is a cosmetic ingredient, not an approved drug. FDA does not pre-approve cosmetic products or ingredients (except some color additives). A product claiming to relax muscles or treat a disease could be regulated as a drug. The industry-funded Cosmetic Ingredient Review panel concluded in 2025 that it is safe as currently used at low concentrations in cosmetics, and that data were insufficient to support higher concentrations. Argireline is not botulinum toxin and is not an FDA-approved alternative to it.
Safety Realities & Impurities
Safety depends on the molecule, formulation, route and evidence. A laboratory purity measurement alone cannot establish safety for human use.
Clinical Trials Registry Records
Official registry records from ClinicalTrials.gov. Study registration does not imply government endorsement or guaranteed efficacy.
Argireline in Treatment of Periorbital Wrinkles [9]
- Planned enrollment
- 70 (patients)
- Posted results
- Pending in registry
- Sponsor
- Mahidol University
- Last updated
- 2011-06-27
A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm [10]
- Planned enrollment
- 24 (patients)
- Posted results
- Available
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Last updated
- 2012-09-06
Acetyl Hexapeptide-8 for Blepharospasm [11]
- Planned enrollment
- 8 (patients)
- Posted results
- Available
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Last updated
- 2016-11-10
Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin [12]
- Planned enrollment
- 14 (patients)
- Posted results
- Pending in registry
- Sponsor
- University of California, Davis
- Last updated
- 2017-04-05
WADA & Anti-Doping Regulations
WADA Anti-Doping Status
Argireline is not prohibited under current World Anti-Doping Agency (WADA) regulations. However, athletes must ensure unregulated preparations or unverified vendor products do not violate Section S0 (Non-approved substances). Last verified: October 2026.
Research Timeline
-
2002
Designed as a toxin mimic
Researchers describe the hexapeptide and its SNARE-interfering activity in the laboratory. [1]
-
2013
Small clinical studies
A 60-person wrinkle study and a 24-person NIH blepharospasm pilot are published. [3]
-
2015
Skin penetration measured
FDA scientists find most applied peptide stays on or in the outer skin layer. [5]
-
2025
Cosmetic safety review
The Cosmetic Ingredient Review panel finds it safe as used at low cosmetic concentrations. [6]
-
2026
Still a cosmetic ingredient
No FDA drug approval; FDA does not pre-approve cosmetic ingredients. [13]
What Researchers Still Don't Know
Long-term safety profiles
Multi-year observational data in broader heterogeneous cohorts remains uncharacterized.
Optimal dose-response thresholds
Comparative trials optimizing minimal effective exposure versus adverse event rates.
Formulation bioavailability
Differences between oral, subcutaneous, and modified peptide delivery vehicles.
References
Primary sources verified against PubMed / NLM and regulatory databases.
-
Original design and laboratory study
A synthetic hexapeptide (Argireline) with antiwrinkle activity ↗ (external website)
- Randomized placebo-controlled study
- Randomized pilot trial
- Small randomized trial
-
Laboratory skin penetration study
In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation ↗ (external website)
-
Cosmetic Ingredient Review safety assessment
Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics ↗ (external website)
- Review
- Case report
-
Registry Record
Argireline in Treatment of Periorbital Wrinkles ↗ (external website)
-
Registry Record
A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm ↗ (external website)
- Registry Record
-
Registry Record
Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin ↗ (external website)
- FDA regulatory explanation
-
FDA regulatory explanation
Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) ↗ (external website)